Drug Profile


Alternative Names: 4SC-201; BYK 408740; RAS 2410; YHI-1001

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nycomed
  • Developer 4SC; Yakult Honsha
  • Class Antineoplastics; Dimethylamines; Hydroxylamines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Hodgkin's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Biliary cancer; Hepatocellular carcinoma; Hodgkin's disease; Mycosis fungoides; Non-small cell lung cancer; Pancreatic cancer; Sezary syndrome
  • Phase I/II Colorectal cancer
  • Phase I Cutaneous T cell lymphoma; Solid tumours
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 13 Sep 2017 Efficacy data from a phase I trial in Biliary cancer and Pancreatic cancer presented at the European Society for Medical Oncology (ESMO-2017)
  • 13 Sep 2017 Yakult Honsha plans a phase II trial (Second-line therapy) for Biliary cancer in Japan
  • 16 May 2017 4SC terminates its licence for resminostat in China, South Korea, Australia, Thailand, Philippines, Indonesia, and Vietnam
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top